About InnoPran XL Consider InnoPran XL™ for 24-hour efficacy Note the reductions in systolic and diastolic blood pressure when measured in the morning and in the evening. Blood pressure measured in the morning (6 AM-10 AM) When measured in the morning, reductions in systolic and diastolic blood pressure in the placebo group were –7.31 mm Hg and –7.09 mm Hg respectively. Blood pressure measured in the evening (5:30 PM-6:30 PM) † [Ref. 1—DOF] When measured in the evening, reductions in systolic and diastolic blood pressure in the placebo group were –7.66 mm Hg and –7.60 mm Hg respectively. † InnoPran XL showed statistical significance as compared to placebo. Results from a randomized, double-blind, parallel, placebo-controlled, multicenter trial in patients with essential hypertension (n=420)

Patients taking InnoPran XL™ should be advised against abrupt interruption or cessation of therapy without their physician’s advice. Exacerbation of angina, and in some cases myocardial infarction, have been reported following abrupt discontinuance or propranolol therapy. Dosage should be gradually reduced over at least a few weeks.

Metabolism of propranolol involves multiple pathways in the cytochrome system P-450 (CYP2D6, 1A2, 2C19) which could potentially lead to drug-drug interactions. Please consult the prescribing information for a list of interaction information.

InnoPran XL is contraindicated in patients with cardiogenic shock; sinus bradycardia, greater than first-degree AV block; and in patients with bronchial asthma or with known hypersensitivity to propranolol hydrochloride.

With InnoPran XL the most common side effects were fatigue 5% vs. 3%, dizziness 7%vs. 2%, and constipation 3% vs. 0%.

Therapeutic blood levels do not necessarily correlate with efficacy.